| Sygnia Itrix Health Innovation AMETF
Type: Active ETF |
JSE code: SYGH |
| Benchmark: Solactive Developed Markets Healthcare 150 | Classification: Global Equity |
| Tax-free investing: Allowed (What is tax-free?) | Market cap: R 200 Million |
| TIC (TER where TIC not indicated): 0.56000000000000005% (What is TER?) | Distribution: Semi-annual | Jan-26: 10.30382, Jul-26: 16.89247 (cents/unit) |
| Returns as per MDD and annualised to the date of the MDD publication.
1 year 11.7% | 3 year 3.5% | 5 year 6.6% | Since listing 6.2% |
|
| Top holdings:
Eli Lilly Ord Shs (10.5%), Johnson & Johnson Ord Shs (6.9%), AbbVie Ord Shs (5.0%), Merck & Co Ord Shs (3.9%), UnitedHealth Group Ord Shs (3.6%), Roche PS Par Shs (3.2%), Novartis Ord Shs (2.8%), Thermo Fisher Scientific Ord Shs (2.7%), Astrazeneca Ord Shs (2.6%), Amgen Ord Shs (2.4%) |
|
| MDD updated: 30 September 2026 (Understanding your MDD)
MDD web link here (BETA): |
|
| Description:
The fund aims to provide investors access to healthcare innovation stocks and deliver long-term capital growth |
|
All data from the issuer Minimum Disclosure Documents (MDD) and updated as they update their MDDs. Please check all data, we take no responsibility for errors.